Presented by
Management Forum
Regulatory Strategies for Orphan Drugs Training Course
This must-attend event will provide an essential overview of the opportunities and challenges presented by orphan drug regulation.
★★★★★ "I believe as a starting point into the world of ODD this was very comprehensive and informative. Ver... more"
27 October 2023
+ 15 February 2024, 24 June 2024, 8 October 2024
from £549
- Format: Live online
- CPD: 6 hours for your records
- Certificate of completion
Course overview
The market for orphan drug products continues to expand and developing new treatments for rare diseases is becoming an increasingly important growth area for many pharmaceutical companies. This interest in rare and orphan diseases is linked not only to the incentives offered by the different regulatory authorities but also to the recent development of advanced therapies.
The interactive course will cover all the key aspects of orphan drug legislation in both the US and EU, including a review of changes proposed in the revised EU orphan drug legislation, and the regulatory processes designed to enable early access to innovative medicines. The programme will help you to assess the strategic considerations of when to apply for orphan designation and to which agency and look at the development of advanced therapies and using orphan drug designation with your ATMP strategy.
A case study session on how to prepare and manage an orphan drug submission will consolidate learning and ensure that you leave the event with practical skills and knowledge that can be put to use in the workplace. The course will allow you not only to learn from our expert trainer but also to share the experiences of other delegates.
Benefits of attending:
- Gain an overview of the orphan medicinal product legislation in the EU and the US
- Receive practical advice on how to prepare and manage orphan submissions
- Assess strategic considerations of when to apply for orphan designation and to what agencies
- Discuss the use of orphan drug designation with your ATMP strategy
This course is part of our Regulatory Affairs Training course collection, which features updates on the latest regulations to registration procedures and strategies.
Who should attend?
This event will be particularly relevant to regulatory affairs professionals who are involved in orphan drug submissions. It will also be of interest to those working in rare diseases who would benefit from an overview of orphan drug designation.
The Regulatory Strategies for Orphan Drugs course will cover:
Orphan Medicinal Product Legislation
- Overview of the legislation in the EU, US and Japan
- Including discussion of the ongoing revision to the EU legislation
- What the Regulations cover and why, what they try to protect
- Benefits of Orphan Drug Designation
- Key Considerations
- Country Submissions
- Differences of Orphan versus non-orphan
- Paediatric Conditions
Obtaining Orphan Drug Designation
- Orphan drug designation in the EU
- Application
- Procedure
- Similarities and differences with the US
- Application, procedure and incentives
- Global Issues around Rare Disease
- Strategic Considerations
- Case Study
Maintenance of Orphan Drug Designation
- How to maintain
- Maintenance during MAA and NDA
- Assessment and Case Study
Global Environment
Marloes van der Geer
Qdossier
Marloes van der Geer works as senior regulatory affairs scientist at Qdossier. Marloes holds a master in Life Sciences (Drug Innovation) from the University of Utrecht, the Netherlands. For nine years she held several positions at Hoffmann-la Roche in Switzerland, including the role of regulatory intelligence manager and regulatory policy lead for the EMEA region. Marloes has been actively involved in several industry associations like EFPIA and IFPMA. Also, she contributed to the ongoing IMI PREFER project in Europe, focused on the generation and use of patient preference data. In 2019, Marloes joined Qdossier. Marloes’ areas of expertise are: eCTD, lean authoring, publishing, biopharmaceuticals (incl. biosimilars), clinical development, regulatory convergence & harmonization and facilitated registration pathways (incl. orphan drugs), local RA activities (e.g. product information management).
Book Regulatory Strategies for Orphan Drugs Live online training
NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:
- 30% off the 2nd delegate*
- 40% off the 3rd delegate*
- 50% off the 4th delegate*
Please contact us for pricing if you are interested in booking 5 or more delegates
27 October 2023
Live online
09:00-17:00 UK (London) (UTC+01)
10:00-18:00 Paris (UTC+02)
04:00-12:00 New York (UTC-04)
Course code 12337
- GBP 649
- EUR 929
- USD 1,049
- 1 day live online training
- Browser-based, no download usually required
- See presenters and interact with fellow attendees
- Download documentation and certification of completion
- Fair transfer and cancellation policy
Not ready to book yet?
for 7 days, no obligation
15 February 2024
Live online
09:00-17:00 UK (London) (UTC+00)
10:00-18:00 Paris (UTC+01)
04:00-12:00 New York (UTC-05)
Course code 13456
- GBP 549 649
- EUR 789 929
- USD 893 1,049
Until 11 Jan
- 1 day live online training
- Browser-based, no download usually required
- See presenters and interact with fellow attendees
- Download documentation and certification of completion
- Fair transfer and cancellation policy
Not ready to book yet?
for 7 days, no obligation
24 June 2024
Live online
09:00-17:00 UK (London) (UTC+01)
10:00-18:00 Paris (UTC+02)
04:00-12:00 New York (UTC-04)
Course code 13737
- GBP 549 649
- EUR 789 929
- USD 893 1,049
Until 20 May
- 1 day live online training
- Browser-based, no download usually required
- See presenters and interact with fellow attendees
- Download documentation and certification of completion
- Fair transfer and cancellation policy
Not ready to book yet?
for 7 days, no obligation
8 October 2024
Live online
09:00-17:00 UK (London) (UTC+01)
10:00-18:00 Paris (UTC+02)
04:00-12:00 New York (UTC-04)
Course code 13919
- GBP 549 649
- EUR 789 929
- USD 893 1,049
Until 03 Sep
- 1 day live online training
- Browser-based, no download usually required
- See presenters and interact with fellow attendees
- Download documentation and certification of completion
- Fair transfer and cancellation policy
Not ready to book yet?
for 7 days, no obligation
* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price.
Reviews of IPI's Regulatory Strategies for Orphan Drugs training course
I believe as a starting point into the world of ODD this was very comprehensive and informative. Very clear and concise.
Sep 26 2022
Khayyam Darr 
Senior Regulatory Affairs Executive, Chiesi Ltd
Jun 20 2022
Superb, excellent delivery and very knowledgeable [...] the best training course I attended in a log time!
John McIntyre 
Senior Consultant, Parexel Ireland USD
Mar 16 2022
Excellent would attend other similar webinar/trainings
Cheryl Dicks 
Sr. Mgr. Regulatory, CANbridge Pharmaceuticals
Sep 26 2022
Very interactive session (nicely done even if remote) Expertise sharing and specific examples shared during the training to emphasize and help to understand key topics
Christine Monteiro 
Senior Regulatory Project Manager , IPSEN
Sep 26 2022
Very instructive training with a very nice speaker. The speaker knew her subject very well and she was able to share some of her experiences with ODD which made the training more interactive.
Laetitia Misslin
Regulatory Affairs Director, Laboratoires DELBERT
Sep 26 2022
Everything was OK
Sarmite Liberte 
Head of Regulatory Affairs, AS Kalceks
Sep 26 2022
Very instructive training with a very nice speaker. Speaker knew her subject very well and she was able to share some of her experiences with ODD which made the training more interactive.
Laetitia Misslin
Regulatory Affairs Director, Laboratoires DELBERT
Mar 10 2021
I liked the webinar very much, because it provided a comprehensive and detailed overview of the ODD process in the EU and other countries. Andrew presented himself as an excellent speaker who answered all questions of the participants in a very detailed and knowledgeable manner.
Burkhard Siefert 
Mar 10 2021
Very dynamic and interesting speaker, interactive webinar.
Anna Sarao
Regulatory Affairs Project Manager, Servier
Mar 10 2021
Very dynamic and interesting speaker, interactive webinar.
Anna Sarao
Regulatory Affairs Project Manager, Servier
United Kingdom
- Blue Reg Pharma Consulting
- Brightwater Research
- Chiesi Ltd
- Fujifilm Kyowa Kirin Biologics
- Galderma (UK) Ltd
- JensonR+ Ltd
- Kyowa Kirin
- NDA Regulatory Science Ltd
- Orphan Reach Ltd
- Vertex Pharmaceuticals (Europe) Limited
France
- Bluereg
- Enterome
- IPSEN
- Laboratoires DELBERT
- Servier
Italy
- Angelini Pharma
- Angelini Pharma s.p.a.
- Sifi S.p.A.
Ireland
- Parexel
- Parexel Ireland USD
Spain
- FAES FARMA SA
- GAT Therapeutics
Belgium
- Imcyse
Germany
- CureVac AG
Latvia
- AS Kalceks
Switzerland
- Takeda
United States of America
- CANbridge Pharmaceuticals
Run Regulatory Strategies for Orphan Drugs Live online for your team
1 day
Typical duration
Pricing from:
- GBP 450
- Per attendee
- Course tailored to your requirements
- At your choice of location, or online
We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.
Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:
